Top Line: Could induction dual-checkpoint blockade expand bladder preservation beyond the “ideal” trimodality candidate?
The Study: The phase II single-arm INDIBLADE trial enrolled 50 patients with cT2-4aN0-2 muscle-invasive bladder cancer, including patients with more advanced disease than typically considered for bladder-sparing approaches. Patients received induction ipilimumab/nivolumab followed by standard chemoradiation if no progression occurred. The primary endpoint bladder-intact event-free survival at two years was 78% with a striking overall survival of 96%. The vast majority (90%) proceeded to chemoradiation while only 12% ultimately required cystectomy. Roughly one-quarter experienced grade 3-4 immune-related adverse events, and nearly one-third required long-term hormone replacement for endocrine effects (eg, hypothyroidism). Exploratory ctDNA analyses were particularly intriguing: patients who were ctDNA-negative after induction immunotherapy enjoyed a 2-year bladder-intact event-free survival exceeding 90%, whereas persistent ctDNA positivity portended markedly worse outcomes (HR 8.3).
TBL: This small phase 2 trial suggests that a sequential strategy of induction ipi/nivo followed by chemoradiation may substantially broaden the pool of patients eligible for bladder preservation and makes a compelling case for a ctDNA response-adapted approach. | Mellema, Nat 2026
The Study: The phase II single-arm INDIBLADE trial enrolled 50 patients with cT2-4aN0-2 muscle-invasive bladder cancer, including patients with more advanced disease than typically considered for bladder-sparing approaches. Patients received induction ipilimumab/nivolumab followed by standard chemoradiation if no progression occurred. The primary endpoint bladder-intact event-free survival at two years was 78% with a striking overall survival of 96%. The vast majority (90%) proceeded to chemoradiation while only 12% ultimately required cystectomy. Roughly one-quarter experienced grade 3-4 immune-related adverse events, and nearly one-third required long-term hormone replacement for endocrine effects (eg, hypothyroidism). Exploratory ctDNA analyses were particularly intriguing: patients who were ctDNA-negative after induction immunotherapy enjoyed a 2-year bladder-intact event-free survival exceeding 90%, whereas persistent ctDNA positivity portended markedly worse outcomes (HR 8.3).
TBL: This small phase 2 trial suggests that a sequential strategy of induction ipi/nivo followed by chemoradiation may substantially broaden the pool of patients eligible for bladder preservation and makes a compelling case for a ctDNA response-adapted approach. | Mellema, Nat 2026